Prostate Cancer
Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE).
October 18, 2023
Radioligand Therapy With 177Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer: Oncological Outcomes and Toxicity Profile.
October 18, 2023
Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer.
October 18, 2023
RAGE as a Novel Biomarker for Prostate Cancer: A Systematic Review and Meta-Analysis.
October 17, 2023
Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
October 17, 2023
Cancer Detection Rate and Abnormal Interpretation Rate of Prostate MRI in Patients with Low-grade Cancer.
October 17, 2023
Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer.
October 17, 2023
Concurrent targeting of HDAC and PI3K to overcome phenotypic heterogeneity of castration-resistant and neuroendocrine prostate cancers.
October 16, 2023
Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews.
October 16, 2023
177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study).
October 16, 2023